1,972
Views
24
CrossRef citations to date
0
Altmetric
REVIEW

Inhaler Devices for Patients with COPD

, &
Pages 523-535 | Published online: 28 Mar 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Kai-Michael Beeh, Piotr Kuna, Massimo Corradi, Isabelle Viaud, Alessandro Guasconi & George Georges. (2021) Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 79-89.
Read now
Kathryn A Collison, Pinal Patel, Andrew F Preece, Richard H Stanford, Raj K Sharma & Gregory Feldman. (2018) A Randomized Clinical Trial Comparing the ELLIPTA and HandiHaler Dry Powder Inhalers in Patients With COPD: Inhaler-Specific Attributes and Overall Patient Preference. COPD: Journal of Chronic Obstructive Pulmonary Disease 15:1, pages 46-50.
Read now
Nicola A Hanania, Suzanne C. Lareau & Barbara P. Yawn. (2017) Safety of inhaled long-acting anti-muscarinic agents in COPD. Postgraduate Medicine 129:5, pages 500-512.
Read now
Suyong Yun Kirby, Chang-Qing Zhu, Edward M. Kerwin, Richard H. Stanford & George Georges. (2016) A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI. COPD: Journal of Chronic Obstructive Pulmonary Disease 13:2, pages 167-175.
Read now

Articles from other publishers (20)

Tamas Erdelyi, Zsofia Lazar, Árpád Farkas, Peter Furi, Attila Nagy & Veronika Müller. (2023) Modeling of pulmonary deposition of agents of open and fixed dose triple combination therapies through two different low-resistance inhalers in COPD: a pilot study. Frontiers in Medicine 10.
Crossref
Yann Renaud, Philipp Suter & Gael Grandmaison. (2023) Patient Characteristics to Consider When Selecting an Inhaler for the Treatment of Chronic Obstructive Pulmonary Disease and Available Assessment Methods: A Narrative Review. Respiration 102:6, pages 416-425.
Crossref
Cheryl Nickerson, Dirk von HollenSara GarbinKetah DotyJeff JaskoChuck Cain. (2022) Pilot Study to Investigate the Benefits of the InnoSpire Go Mesh Nebulizer Compared to Jet Nebulizers in the Treatment of Stable COPD. Journal of Aerosol Medicine and Pulmonary Drug Delivery 35:4, pages 186-195.
Crossref
David M. G. Halpin & Donald A. Mahler. (2022) A Systematic Review of Published Algorithms for Selecting an Inhaled Delivery System in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society 19:7, pages 1213-1220.
Crossref
Jill A. Ohar, Andrea Bauer, Sanjay Sharma & Shahin Sanjar. (2020) In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®. Pulmonary Therapy 6:2, pages 289-301.
Crossref
Taciano Rocha, Catarina Rattes, Caio Morais, Renata Souza, Nadja Rolim, Simone Brandão, James B. Fink & Armèle Dornelas de Andrade. (2020) Predictive anatomical factors of lung aerosol deposition in obese individuals. Would modified mallampati score be relevant? Clinical trial. Respiratory Medicine 171, pages 106083.
Crossref
Torben Sebastian Last, Niclas Roxhed & Goran Stemme. (2020) A Self-Sealing Spray Nozzle for Aerosol Drug Delivery. Journal of Microelectromechanical Systems 29:2, pages 182-189.
Crossref
C. Moura, T. Casimiro, E. Costa & A. Aguiar-Ricardo. (2019) Optimization of supercritical CO2-assisted spray drying technology for the production of inhalable composite particles using quality-by-design principles. Powder Technology 357, pages 387-397.
Crossref
Martyn F. Biddiscombe & Omar S. Usmani. (2018) Is there room for further innovation in inhaled therapy for airways disease?. Breathe 14:3, pages 216-224.
Crossref
James F. Donohue, Thomas Goodin, Robert Tosiello & Alistair Wheeler. (2017) Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies. Respiratory Research 18:1.
Crossref
James B. Fink, Lisa Molloy, John S. Patton, Valdecir Castor Galindo-Filho, Jacqueline de Melo Barcelar, Luciana Alcoforado, Simone Cristina Soares Brandão & Armèle Dornelas de Andrade. (2017) Good Things in Small Packages: an Innovative Delivery Approach for Inhaled Insulin. Pharmaceutical Research 34:12, pages 2568-2578.
Crossref
Gary T. Ferguson, Thomas Goodin, Robert Tosiello, Alistair Wheeler & Edward Kerwin. (2017) Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respiratory Medicine 132, pages 251-260.
Crossref
Edward Kerwin, James F. Donohue, Thomas Goodin, Robert Tosiello, Alistair Wheeler & Gary T. Ferguson. (2017) Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respiratory Medicine 132, pages 238-250.
Crossref
Imran SulaimanJansen SeheultNirmal SadasivuniElaine MacHaleIsabelle KillaneSpiros GiannoutsosBreda CushenMatshediso Constantina MokokaAoife Sartini BhreathnachFiona BolandRichard B. ReillyRichard W. Costello. (2017) The Impact of Common Inhaler Errors on Drug Delivery: Investigating Critical Errors with a Dry Powder Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery 30:4, pages 247-255.
Crossref
Shelby Dougall, Jennifer Bolt, William Semchuk & Tanya Winkel. (2016) Inhaler assessment in COPD patients. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 149:5, pages 268-273.
Crossref
David PrimeWilfried de BackerMelanie HamiltonAnthony CahnAndrew PreeceDennis KelleherAmanda BainesAlison MooreNoushin BrealeyJackie Moynihan. (2015) Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA ® Dry Powder Inhaler . Journal of Aerosol Medicine and Pulmonary Drug Delivery 28:6, pages 486-497.
Crossref
Mario Cazzola & Paola Rogliani. 2015. Controversies in COPD. Controversies in COPD 213 223 .
Katherine A. Lyseng-Williamson & Gillian M. Keating. (2015) Tiotropium Respimat® Soft Mist™ inhaler: a guide to its use in chronic obstructive pulmonary disease (COPD) in the EU. Drugs & Therapy Perspectives 31:2, pages 39-44.
Crossref
Gillian M. Keating. (2014) Tiotropium Respimat® Soft Mist™ Inhaler: A Review of Its Use in Chronic Obstructive Pulmonary Disease. Drugs 74:15, pages 1801-1816.
Crossref
Daan A. De Coster & Melvyn Jones. (2014) Tailoring of corticosteroids in COPD management. Current Respiratory Care Reports 3:3, pages 121-132.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.